Cidara presents new preclinical data on drug-Fc conjugate candidate

Cidara Therapeutics announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate candidate at the ESMO Immuno-Oncology Annual Congress. Cidara also presented new preclinical data on CBO421, its first-in-class CD73-targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland. “We are thrilled to be presenting promising preclinical data on our novel multi-specific DFC in colorectal cancer for the first time at ESMO-IO this year,” said Jeffrey Stein, Ph.D., president and chief executive officer at Cidara. “Dual inhibition of both CD73 and PD-1 checkpoint pathways with a single DFC contributed to significant tumor growth reduction, highlighting the potential clinical benefits of this first-in-class multi-specific inhibitor derived from our Cloudbreak platform.” Title: Discovery of a Novel, Dual CD73 & PD-1 Targeting Multi-specific Drug Fc-Conjugate for the Treatment of Cancer. Key highlights: CD73/PD-1 DFC is a potent inhibitor of hCD73 and hPD-1; DFC reduced tumor growth by 56% at 1mg/kg and greater than70% at 3mg/kg doses; DFC demonstrated superior activity to a pembrolizumab biosimilar antibody and a matched CD73 DFC at 1/3 the dose of the respective monotherapies. Title: Discovery of CBO421, a First-in-Class Drug Fc-Conjugate, Targeting CD73 in Cancer. Key highlights: CBO421 is a potent, AMP-competitive inhibitor of CD73 that demonstrates a differentiated in vitro activity profile across several assays compared with small molecule and antibody inhibitors of CD73 in clinical development; The in vitro potency, multiple mechanisms of action, and favorable pharmacokinetics profile of CBO421 translated to antitumor efficacy in monotherapy and in combination with PD-1 therapy